Dihydrotestosterone (DHT) treatment significantly increased PEX10 expression at the mRNA and protein levels in prostate cancer cells, including C4-2 and LNCaP cells, while enzalutamide treatment decreased PEX10 expression, which is consistent with the changes in KLK3 (Fig. 5C–E) and our previous conclusions. Here, PEX10 is linked to prostate cancer.